Phase 2
Development Phase
0
Upcoming Catalysts
0
Historical Events
1
Regulatory Approvals
No Catalysts Found
No catalyst events have been recorded for this drug yet.
10 competitors in Diabetes Mellitus, Type 2
No patent data available. Pre-approval drugs may not have Orange Book listings.
Eperzan
Eperzan is indicated for the treatment of type 2 diabetes mellitus in adults to improve glycaemic control as: Monotherapy When diet and exercise alone do not provide adequate glycaemic control in patients for whom use of metformin is considered inappropriate due to contraindications or intolerance. Add-on combination therapy In combination with other glucose-lowering medicinal products including basal insulin, when these, together with diet and exercise, do not provide adequate glycaemic control (see section 4.4 and 5.1 for available data on different combinations).
View on EMADental Caries
Hepatitis B
Pulmonary Disease, Chronic Obstructive
Acute Coronary Syndrome
Infections, Meningococcal